ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.7153
0.21%
Brent Oil
83.305
0.12%
Bitcoin
65,496.59
0.39%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Alexion Pharmaceuticals Inc (ALXN)

  7. Alexion Pharmaceuticals Inc (ALXN) Noticias

ALXN

Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALXN
FechaHoraFuenteTítuloSímboloCompañía
28/07/202303:54KR Market News알렉시온, 화이자 유전자 치료제를 10억 달러 인수 합의NASDAQ:ALXNAlexion Pharmaceuticals Inc
28/07/202303:23KR Market News아스트라제네카, 항암제 수요로 2분기 결과 예상치 상회NASDAQ:ALXNAlexion Pharmaceuticals Inc
26/07/202105:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ALXNAlexion Pharmaceuticals Inc
23/07/202115:55Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALXNAlexion Pharmaceuticals Inc
22/07/202108:09Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ALXNAlexion Pharmaceuticals Inc
22/07/202105:27Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALXNAlexion Pharmaceuticals Inc
21/07/202108:12Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ALXNAlexion Pharmaceuticals Inc
15/07/202118:01PR Newswire (US)Moderna Set to Join S&P 500NASDAQ:ALXNAlexion Pharmaceuticals Inc
15/07/202115:05Business WireAlexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized My...NASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202119:00GlobeNewswire Inc.Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202111:13Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202104:11Dow Jones NewsAstraZeneca Says $39 Billion Alexion Deal Set for Completion After UK Clearance -- UpdateNASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202101:30Dow Jones NewsUK Regulator Clears AstraZeneca's Alexion DealNASDAQ:ALXNAlexion Pharmaceuticals Inc
11/06/202102:01Business WireCaelum & Alexion Present Additional Phase 2 Data Reinforcing Safety & Tolerability of CAEL-101 in AL Amyloidosis at the Europ...NASDAQ:ALXNAlexion Pharmaceuticals Inc
07/06/202112:55Business Wire Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children & Adolescents with Paroxysmal Nocturnal Hemog...NASDAQ:ALXNAlexion Pharmaceuticals Inc
04/06/202115:22Dow Jones NewsAstraZeneca Taps Alexion Executive for CFO Job -- UpdateNASDAQ:ALXNAlexion Pharmaceuticals Inc
04/06/202101:40Dow Jones NewsAstraZeneca Names Aradhana Sarin as Next CFONASDAQ:ALXNAlexion Pharmaceuticals Inc
27/05/202101:43Dow Jones NewsAstraZeneca Prices EUR800 Million Bond OfferingNASDAQ:ALXNAlexion Pharmaceuticals Inc
26/05/202101:43Dow Jones NewsAstraZeneca Prices $7 Billion Bond Offering to Partly Fund Alexion AcquisitionNASDAQ:ALXNAlexion Pharmaceuticals Inc
25/05/202101:41Dow Jones NewsUK Watchdog Starts Investigation Into AstraZeneca's Acquisition of AlexionNASDAQ:ALXNAlexion Pharmaceuticals Inc
13/05/202107:06Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ALXNAlexion Pharmaceuticals Inc
12/05/202115:14Business WireCaelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
12/05/202115:01Business WireAlexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual CongressNASDAQ:ALXNAlexion Pharmaceuticals Inc
12/05/202103:52TipRanksAlexion Investors Approve Acquisition By AstraZenecaNASDAQ:ALXNAlexion Pharmaceuticals Inc
11/05/202115:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALXNAlexion Pharmaceuticals Inc
11/05/202108:28Business WireAlexion Shareholders Approve Acquisition by AstraZenecaNASDAQ:ALXNAlexion Pharmaceuticals Inc
30/04/202107:27Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALXNAlexion Pharmaceuticals Inc
30/04/202107:00Business WireAlexion Reports First Quarter 2021 ResultsNASDAQ:ALXNAlexion Pharmaceuticals Inc
28/04/202116:00Business WireUPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
20/04/202107:00Business WireAlexion to Report First Quarter 2021 Results on Monday, May 3, 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALXN

Su Consulta Reciente

LSE
3CRL
Etfs 3x Wti
COIN
SQRUSD
sQuorum
COIN
OCEANUST
Ocean Protocol
USOTC
CEZZY
CEZ AS (PK)
LSE
GDYO
Gibbs & Dandy
AMEX
SHAG
WisdomTree Yield Enhance...
LSE
BN28
Citi Fun 24
USOTC
WDRP
Wanderport (PK)
BIT
ELOVD
UBS Lux Fd Sol Factor MS...
NASDAQ
FYSMRX
Balanced Income Select P...
EU
U357S
U357S
LSE
XIDD
Xindonesiasw 1c
EU
H843T
H843T
HUOB
KCTUSDT
Konnect
LSE
CCLA
EU
5544T
5544T
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados